- Barnier promises compromise from France's embattled new govt
- Zelensky arrives in US to explain war plan to Biden
- Barca rout Villarreal but Ter Stegen hurt, Atletico draw at Rayo
- Darnold shines for Vikings, Steelers and Eagles win
- Atletico held to draw at Rayo Vallecano
- Marseille stun Lyon with 95th-minute winner after early red card
- Gabbia ends AC Milan's derby pain with late winner against Inter
- Surging Ko claims LPGA Queen City crown in spectacular style
- 'Impossible': Alcaraz shoots down Federer comparisons after Laver Cup win
- Scholz's party beats far-right AfD in east German state vote
- Verstappen says 'silly' swearing row could hasten F1 exit
- Calls for Israel and Hezbollah to step back from the abyss
- Israel and Hezbollah urged to avoid 'catastrophe'
- Colombia battles fires as drought fuels Latin American flames
- Pressure piles on new French government from day one
- Arteta proud as Arsenal salvage point from 'impossible' task
- Barca rout Villarreal in thriller but Ter Stegen hurt
- Roma stroll past Udinese as fans protest De Rossi sacking
- Horschel outduels McIlroy to win PGA Championship play-off
- Audiences summon 'Beetlejuice' to top of N. America box office for third week
- Stones salvages point for Man City against 10-man Arsenal
- Egypt fears 'all out' regional war: foreign minister to AFP
- Last-gasp Boniface gives Leverkusen victory, Stuttgart outclass Dortmund
- Scholz's party beats far-right AfD in east German state vote: projections
- Olympic champion Evenepoel retains world title in 'toughest time trial'
- Horschel's eagle beats McIlroy in PGA Championship play-off
- Mourners at commander's funeral express loyalty to Hezbollah
- Norris hails his 'mega' McLaren after dominant win at Singapore
- Monaco beat Le Havre to join PSG at the top of Ligue 1
- Scholz's party narrowly leads far-right AfD in east German state vote: exit polls
- New leftist president vows to 'rewrite Sri Lankan history'
- UN adopts pact to tackle volatile future for mankind
- Leclerc hails Ferrari fightback from torrid Singapore GP qualifying
- Belgian Evenepoel retains world title in 'toughest time trial'
- Sosa rescues point for Forest against Brighton
- Last-gasp Boniface gives Leverkusen victory over Wolfsburg in seven-goal thriller
- Swiss voters reject environment, pensions reforms: official results
- No fairytale ending for Ricciardo after 13 years in Formula One
- Israel and Hezbollah urged to step back from the brink
- What is the UN's 'Pact for the Future'?
- Norris dominates Singapore Grand Prix to cut Verstappen's title lead
- From bullets to ballots: Sri Lanka's comrade president-elect
- McLaren's Lando Norris wins Singapore GP to narrow F1 title race
- UN adopts pact promising to build 'brighter future' for humanity
- Military escalation not in Israel's 'best interest': White House
- Marxist leader declared Sri Lanka's president-elect
- Classes resume at Bangladesh university at heart of protests
- 'Barely anyone left': Sudan's El-Fasher devastated by fighting
- 'Warrior' Joshua vows to fight on despite Dubois mauling
- Martin extends MotoGP lead as Bastianini wins at Misano and Bagnaia crashes out
Weight-loss drug maker Novo Nordisk's profit surges as sales boom
Danish pharmaceutical giant Novo Nordisk posted bumper profits for 2023 on Wednesday, driven by blockbuster sales of diabetes and obesity treatments that helped it become Europe's most valuable company.
The century-old company has also turned into a major driver of Denmark's economy as sales of diabeties medication Ozempic and obesity drug Wegovy have boomed.
Novo Nordisk said its net profit rose 51 percent to 83.7 billion kroner ($12.1 billion) last year -- more than 1.5 billion kroner higher than forecast by analysts surveyed by financial data firm FactSet.
It said sales for obesity and diabetes drugs surged by 42 percent at constant exchange rates to 215.1 billion kroner last year.
Overall sales rose by 36 percent to 232.3 billion kroner in 2023.
"It looks like Novo Nordisk can explain all of the growth in the Danish economy in 2023 and that it will be just as important this year," Danske Bank chief analyst Las Olsen told AFP.
He cited the company's effect on job creation, tax contributions and dividends paid to shareholders.
Denmark's economy is expected to grow by 1.7 percent in 2023, according to a central bank forecast.
- 'Strong performance' -
Ozempic, an injectable medication, became wildly popular on social networks for its slimming properties even though its intended use is to combat diabetes.
It also makes Wegovy, which has the same active ingredient as Ozempic in a different dose and was approved by US regulators to treat obesity.
The treatments are popular among celebrities and their success have turned Novo Nordisk into a darling of investors who drove up the company's shares so high last year that it became Europe's largest group by market capitalisation.
"We are very pleased with the strong performance in 2023 reflecting that more than 40 million people are now benefiting from our innovative diabetes and obesity treatments," chief executive Lars Fruergaard Jorgensen said in a statement.
"We continue to make progress on our strategic aspirations. Our focus in 2024 will be on reaching more patients, progressing and expanding our pipeline as well as the continued significant expansion of our production capacity," he added.
In 2023, Novo Nordisk invested around 75 billion kroner to expand its production sites, which have struggled to meet rising demand.
The investments concern primarily two sites in Denmark and one in France.
- Ozempic top seller -
More than 10 percent of the world's population suffers from diabetes, with the number of adult diabetics seen rising by 46 percent by 2045, according to the International Diabetes Federation.
Ozempic is now the world's top-selling diabetes drug, with Novo Nordisk holding 33.8 percent of the market.
It is officially only prescribed for diabetes, though it has become popular for its weight-loss properties.
Wegovy is an anti-obesity treatment that was launched in the United States in 2021 and is now also available in Denmark, Germany, Norway and the UK.
Sales of Wegovy soared by 154 percent in 2023.
The World Health Organization says more than a billion people suffer from obesity, a chronic condition that increases the risk of cardiovascular disease, diabetes, some forms of cancer and complications, such as with Covid-19.
Obesity, which is notoriously difficult and costly to treat, may be caused by lifestyle factors as well as genetics.
If prevention and medical treatments don't improve, the World Obesity Federation says it expects half of the world's population, 51 percent, to be either overweight or obese by 2035.
According to its calculations, the economic impact of such a development would exceed $4 trillion per year.
Novo Nordisk, which has 64,000 employees in 80 countries, said it expected its overall sales to increase by 18-26 percent in 2024.
Danske Bank analyst Olsen noted that while Novo Nordisk's growth "cannot go on forever", the "income, investment and knowledge from the current success will continue to benefit Denmark, as long as we maintain a flexible economy that can handle future shocks."
M.Thompson--AMWN